Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.
Epidermal growth factor receptor (EGFR) mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation frequency on lung adenocarcinoma is still limited to retrospective studies. The PIONEER study (NCT01185314) is a prospective mo...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4657882?pdf=render |
| _version_ | 1819104697082970112 |
|---|---|
| author | Yuankai Shi Junling Li Shucai Zhang Mengzhao Wang Shujun Yang Ning Li Gang Wu Wei Liu Guoqing Liao Kaican Cai Liang'an Chen Meizhen Zheng Ping Yu Xiuwen Wang Yunpeng Liu Qisen Guo Ligong Nie Jiwei Liu Xiaohong Han |
| author_facet | Yuankai Shi Junling Li Shucai Zhang Mengzhao Wang Shujun Yang Ning Li Gang Wu Wei Liu Guoqing Liao Kaican Cai Liang'an Chen Meizhen Zheng Ping Yu Xiuwen Wang Yunpeng Liu Qisen Guo Ligong Nie Jiwei Liu Xiaohong Han |
| author_sort | Yuankai Shi |
| collection | DOAJ |
| description | Epidermal growth factor receptor (EGFR) mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation frequency on lung adenocarcinoma is still limited to retrospective studies. The PIONEER study (NCT01185314) is a prospective molecular epidemiology study in Asian patients with newly diagnosed advanced lung adenocarcinoma, aiming to prospectively analyze EGFR mutation status in IIIB/IV treatment-naïve lung adenocarcinomas in Asia. We report the mainland China subset results. Eligible patients (≥20 yrs old, IIIB/IV adenocarcinoma and treatment-naïve) were registered in 17 hospitals in mainland China. EGFR was tested for mutations by amplification refractory mutation system using biopsy samples. Demographic and clinical characteristics were collected for subgroup analyses. A total of 747 patients were registered. Successful EGFR mutation analysis was performed in 741, with an overall mutation rate of 50.2%. The EGFR active mutation rate is 48.0% (with 1.3% of combined active and resistance mutations). Tobacco use (>30 pack-year vs. 0-10 pack-year, OR 0.27, 95%CI: 0.17-0.42) and regional lymph nodes involvement (N3 vs. N0, OR 0.47, 95%CI: 0.29-0.76) were independent predictors of EGFR mutation in multivariate analysis. However, even in regular smokers, the EGFR mutation frequency was 35.3%. The EGFR mutation frequency was similar between diverse biopsy sites and techniques. The overall EGFR mutation frequency of the mainland China subset was 50.2%, independently associated with the intensity of tobacco use and regional lymph nodes involvement. The relatively high frequency of EGFR mutations in the mainland China subset suggest that any effort to obtain tissue sample for EGFR mutation testing should be encouraged. |
| first_indexed | 2024-12-22T02:10:28Z |
| format | Article |
| id | doaj.art-baaa4a1dda684e5684b982d8c960de64 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T02:10:28Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-baaa4a1dda684e5684b982d8c960de642022-12-21T18:42:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011011e014351510.1371/journal.pone.0143515Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.Yuankai ShiJunling LiShucai ZhangMengzhao WangShujun YangNing LiGang WuWei LiuGuoqing LiaoKaican CaiLiang'an ChenMeizhen ZhengPing YuXiuwen WangYunpeng LiuQisen GuoLigong NieJiwei LiuXiaohong HanEpidermal growth factor receptor (EGFR) mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation frequency on lung adenocarcinoma is still limited to retrospective studies. The PIONEER study (NCT01185314) is a prospective molecular epidemiology study in Asian patients with newly diagnosed advanced lung adenocarcinoma, aiming to prospectively analyze EGFR mutation status in IIIB/IV treatment-naïve lung adenocarcinomas in Asia. We report the mainland China subset results. Eligible patients (≥20 yrs old, IIIB/IV adenocarcinoma and treatment-naïve) were registered in 17 hospitals in mainland China. EGFR was tested for mutations by amplification refractory mutation system using biopsy samples. Demographic and clinical characteristics were collected for subgroup analyses. A total of 747 patients were registered. Successful EGFR mutation analysis was performed in 741, with an overall mutation rate of 50.2%. The EGFR active mutation rate is 48.0% (with 1.3% of combined active and resistance mutations). Tobacco use (>30 pack-year vs. 0-10 pack-year, OR 0.27, 95%CI: 0.17-0.42) and regional lymph nodes involvement (N3 vs. N0, OR 0.47, 95%CI: 0.29-0.76) were independent predictors of EGFR mutation in multivariate analysis. However, even in regular smokers, the EGFR mutation frequency was 35.3%. The EGFR mutation frequency was similar between diverse biopsy sites and techniques. The overall EGFR mutation frequency of the mainland China subset was 50.2%, independently associated with the intensity of tobacco use and regional lymph nodes involvement. The relatively high frequency of EGFR mutations in the mainland China subset suggest that any effort to obtain tissue sample for EGFR mutation testing should be encouraged.http://europepmc.org/articles/PMC4657882?pdf=render |
| spellingShingle | Yuankai Shi Junling Li Shucai Zhang Mengzhao Wang Shujun Yang Ning Li Gang Wu Wei Liu Guoqing Liao Kaican Cai Liang'an Chen Meizhen Zheng Ping Yu Xiuwen Wang Yunpeng Liu Qisen Guo Ligong Nie Jiwei Liu Xiaohong Han Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. PLoS ONE |
| title | Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. |
| title_full | Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. |
| title_fullStr | Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. |
| title_full_unstemmed | Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. |
| title_short | Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. |
| title_sort | molecular epidemiology of egfr mutations in asian patients with advanced non small cell lung cancer of adenocarcinoma histology mainland china subset analysis of the pioneer study |
| url | http://europepmc.org/articles/PMC4657882?pdf=render |
| work_keys_str_mv | AT yuankaishi molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT junlingli molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT shucaizhang molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT mengzhaowang molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT shujunyang molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT ningli molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT gangwu molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT weiliu molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT guoqingliao molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT kaicancai molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT lianganchen molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT meizhenzheng molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT pingyu molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT xiuwenwang molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT yunpengliu molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT qisenguo molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT ligongnie molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT jiweiliu molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy AT xiaohonghan molecularepidemiologyofegfrmutationsinasianpatientswithadvancednonsmallcelllungcancerofadenocarcinomahistologymainlandchinasubsetanalysisofthepioneerstudy |